🇸🇪𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗦𝘄𝗲𝗱𝗲𝗻: 𝗧𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗠𝗮𝗻𝗮𝗴𝗲𝗱 𝗘𝗻𝘁𝗿𝘆 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 (𝗠𝗘𝗔𝘀)🇸🇪 How are MEAs reshaping access to novel therapies in Sweden? In Sweden, MEAs are now central tools for ensuring access to innovative therapies while managing healthcare costs. Currently, 𝗼𝘃𝗲𝗿 𝗵𝗮𝗹𝗳 𝗼𝗳 𝗻𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘀𝗮𝗹𝗲𝘀 𝗮𝗿𝗲 𝗰𝗼𝘃𝗲𝗿𝗲𝗱 𝗯𝘆 𝗠𝗘𝗔𝘀, which often use confidential rebates and outcome-based payments to balance affordability and value. 🔍 𝗛𝗼𝘄 𝗠𝗘𝗔𝘀 𝗪𝗼𝗿𝗸 MEAs complement Sweden’s value-based pricing system for outpatient drugs, addressing uncertainties around costs and patient volumes while allowing flexibility for local needs through three key players: • 𝗧𝗟𝗩 (𝗗𝗲𝗻𝘁𝗮𝗹 𝗮𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗔𝗴𝗲𝗻𝗰𝘆): Sets national standards for cost-effectiveness and access. • 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗔𝘂𝘁𝗵𝗼𝗿𝗶𝘁𝗶𝗲𝘀: Negotiate agreements to align with local budgets and healthcare priorities. • 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀: Collaborate to support both access and cost containment. 🚀 𝗙𝘂𝘁𝘂𝗿𝗲 𝗧𝗿𝗲𝗻𝗱𝘀 𝗮𝗻𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 With drug costs rising around 5% annually, MEAs are increasingly critical for maintaining sustainable access to high-cost therapies. TLV is exploring new MEA models, including outcome-based payments, to better support advanced therapies. 📊 𝗣𝗼𝗹𝗶𝗰𝘆 𝗮𝗻𝗱 𝗘𝗾𝘂𝗶𝘁𝘆 𝗘𝗾𝘂𝗮𝗹 𝗮𝗰𝗰𝗲𝘀𝘀 is a cornerstone of Sweden’s healthcare system and remains high on the political agenda. While MEAs can accelerate access to innovative therapies, Sweden’s decentralized healthcare model—where regional authorities negotiate MEAs—can lead to variations in access across regions. The government is considering steps to centralize certain aspects of medicine access to ensure equitable access across all regions. 📈 𝗪𝗵𝗮𝘁 𝗧𝗵𝗶𝘀 𝗠𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝗣𝗵𝗮𝗿𝗺𝗮 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 For companies entering the Swedish market, understanding both TLV’s value-based pricing approach and the nuances of regional MEA negotiations is essential. Monitoring policy developments toward national coordination will also be crucial. Balancing cost-effectiveness with equitable access will continue to be fundamental—especially for high-cost, innovative therapies. Interested in navigating MEAs and staying ahead of policy changes in Sweden? 📩 Contact Charlotte Langbo and Elisabetta Cesari to discuss how we can help you navigate these complexities and optimize access to your innovative products in Sweden! Contribution by Elisabetta Cesari, our Senior Associate at Inbeeo! #ManagedEntryAgreements #MarketAccess #InnovativeTherapies #Sweden #EquitableAccess
